✦ LIBER ✦

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial

✍ Scribed by Dungan, Kathleen M; Povedano, Santiago Tofé; Forst, Thomas; González, José G González; Atisso, Charles; Sealls, Whitney; Fahrbach, Jessie L

Book ID: 126598617
Publisher: The Lancet
Year: 2014
Tongue: English
Weight: 535 KB
Volume: 384
Category: Article
ISSN: 0140-6736
DOI: 10.1016/S0140-6736(14)60976-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Exenatide once weekly versus liraglutide

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

✍ Buse, John B; Nauck, Michael; Forst, Thomas; Sheu, Wayne H-H; Shenouda, Sylvia K 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 389 KB

Once-weekly albiglutide versus once-dail

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study

✍ Pratley, Richard E; Nauck, Michael A; Barnett, Anthony H; Feinglos, Mark N; Oval 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 288 KB

Once-Weekly Exenatide Versus Once- or Tw

Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir: Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas

✍ Davies, M.; Heller, S.; Sreenan, S.; Sapin, H.; Adetunji, O.; Tahbaz, A.; Vora, 📂 Article 📅 2012 🏛 American Diabetes Association 🌐 English ⚖ 223 KB

Efficacy and safety of insulin degludec

Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials

✍ Zinman, Bernard; DeVries, J Hans; Bode, Bruce; Russell-Jones, David; Leiter, Law 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 337 KB

Insulin degludec, an ultra-long-acting b

Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial

✍ Bernard Zinman; Greg Fulcher; Paturi V Rao; Nihal Thomas; Lars A Endahl; Thue Jo 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 203 KB

Efficacy and safety of canagliflozin ver

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

✍ Cefalu, William T; Leiter, Lawrence A; Yoon, Kun-Ho; Arias, Pablo; Niskanen, Leo 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 489 KB